Summit Therapeutics
SMMT
20 hedge funds and large institutions have $53.3M invested in Summit Therapeutics in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 3 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
20% more capital invested
Capital invested by funds: $44.5M → $53.3M (+$8.81M)
0.06% less ownership
Funds ownership: 5.69% → 5.63% (-0.06%)
5% less funds holding
Funds holding: 21 → 20 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$3.12M |
| 2 |
Morgan Stanley
New York
|
+$2M |
| 3 |
Axa
Paris,
France
|
+$690K |
| 4 |
Renaissance Technologies
New York
|
+$612K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.35M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.15M |
| 3 |
Millennium Management
New York
|
-$958K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$445K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$89.5K |
SMMT Hedge Fund Activity: Q1 2018 in Review
20 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2018, worth a combined $53.3M — up 20% from $44.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SMMT and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 8 added.
The largest buyer was Polar Capital, adding an estimated $3.12M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.35M sold.
- 20 institutional investors held Summit Therapeutics (SMMT) as of Q1 2018, down from 21 in Q4 2017.
- Funds reported $53.3M of Summit Therapeutics stock for Q1 2018, up 20% quarter-over-quarter.
- 2 funds opened new Summit Therapeutics positions in Q1 2018 and 3 closed out, a net change of -1 holder.
- The largest Summit Therapeutics buyer in Q1 2018 was Polar Capital, an estimated $3.12M added.
- The largest Summit Therapeutics seller in Q1 2018 was Sphera Funds Management, an estimated $2.35M sold.
Based on aggregated 13F filings for Q1 2018.